{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,22]],"date-time":"2026-07-22T20:32:15Z","timestamp":1784752335032,"version":"3.55.0"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"DOI":"10.1186\/s12888-025-06856-7","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T16:00:47Z","timestamp":1748880047000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Memantine augmentation of escitalopram in treatment of executive function among patients with obsessive-compulsive disorder (OCD): a double-blind placebo-controlled randomized clinical trial"],"prefix":"10.1186","volume":"25","author":[{"given":"Hasan","family":"Mirzazadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younes","family":"Ghaeminia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amin","family":"Mohamad Niaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammadsadegh","family":"Kamran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leila","family":"Razeghian Jahromi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Moshfeghinia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"6856_CR1","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association. Diagnostic and statistical manual of mental disorders (DSM-5\u00ae). Am Psychiatric Pub; 2013.","DOI":"10.1176\/appi.books.9780890425596"},{"issue":"9688","key":"6856_CR2","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/S0140-6736(09)60240-3","volume":"374","author":"JS Abramowitz","year":"2009","unstructured":"Abramowitz JS, Taylor S, McKay D. Obsessive-compulsive disorder. Lancet. 2009;374(9688):491\u20139.","journal-title":"Lancet"},{"issue":"1","key":"6856_CR3","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/mp.2008.94","volume":"15","author":"AM Ruscio","year":"2010","unstructured":"Ruscio AM, Stein DJ, Chiu WT, Kessler RC. The epidemiology of obsessive-compulsive disorder in the National comorbidity survey replication. Mol Psychiatry. 2010;15(1):53\u201363.","journal-title":"Mol Psychiatry"},{"key":"6856_CR4","doi-asserted-by":"crossref","unstructured":"Jansen M, Overgaauw S, De Bruijn ERA. Social cognition and Obsessive-Compulsive disorder: A review of subdomains of social functioning. Front Psychiatry. 2020;11.","DOI":"10.3389\/fpsyt.2020.00118"},{"issue":"2","key":"6856_CR5","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4103\/0019-5545.31598","volume":"48","author":"S Tarafder","year":"2006","unstructured":"Tarafder S, Bhattacharya P, Paul D, Bandyopadhyay G, Mukhopadhyay P. Neuropsychological disposition and its impact on the executive functions and cognitive style in patients with obsessive-compulsive disorder. Indian J Psychiatry. 2006;48(2):102\u20136.","journal-title":"Indian J Psychiatry"},{"issue":"1","key":"6856_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.psc.2022.10.004","volume":"46","author":"SD Spencer","year":"2023","unstructured":"Spencer SD, Stiede JT, Wiese AD, Goodman WK, Guzick AG, Storch EA. Cognitive-Behavioral therapy for Obsessive-Compulsive disorder. Psychiatr Clin North Am. 2023;46(1):167\u201380.","journal-title":"Psychiatr Clin North Am"},{"issue":"Suppl 1","key":"6856_CR7","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1471-244X-14-S1-S1","volume":"14","author":"MA Katzman","year":"2014","unstructured":"Katzman MA, Bleau P, Blier P, Chokka P, Kjernisted K, Van Ameringen M, et al. Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders. BMC Psychiatry. 2014;14(Suppl 1):S1.","journal-title":"BMC Psychiatry"},{"issue":"Suppl 1","key":"6856_CR8","doi-asserted-by":"publisher","first-page":"S74","DOI":"10.4103\/0019-5545.196976","volume":"59","author":"YC Janardhan Reddy","year":"2017","unstructured":"Janardhan Reddy YC, Sundar AS, Narayanaswamy JC, Math SB. Clinical practice guidelines for Obsessive-Compulsive disorder. Indian J Psychiatry. 2017;59(Suppl 1):S74\u201390.","journal-title":"Indian J Psychiatry"},{"issue":"Suppl 1","key":"6856_CR9","first-page":"S51","volume":"61","author":"A Thamby","year":"2019","unstructured":"Thamby A, Jaisoorya TS. Antipsychotic augmentation in the treatment of obsessive-compulsive disorder. Indian J Psychiatry. 2019;61(Suppl 1):S51\u20137.","journal-title":"Indian J Psychiatry"},{"issue":"1","key":"6856_CR10","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12888-021-03642-z","volume":"22","author":"S Askari","year":"2022","unstructured":"Askari S, Mokhtari S, Shariat SV, Shariati B, Yarahmadi M, Shalbafan M. Memantine augmentation of Sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial. BMC Psychiatry. 2022;22(1):34.","journal-title":"BMC Psychiatry"},{"issue":"2","key":"6856_CR11","doi-asserted-by":"publisher","first-page":"149","DOI":"10.4103\/0972-6748.132930","volume":"22","author":"AK Bakhla","year":"2013","unstructured":"Bakhla AK, Verma V, Soren S, Sarkhel S, Chaudhury S. An open-label trial of memantine in treatment-resistant obsessive-compulsive disorder. Ind Psychiatry J. 2013;22(2):149\u201352.","journal-title":"Ind Psychiatry J"},{"key":"6856_CR12","doi-asserted-by":"publisher","first-page":"e39223","DOI":"10.2196\/39223","volume":"12","author":"A Maraone","year":"2023","unstructured":"Maraone A, Trebbastoni A, Di Vita A, D\u2019Antonio F, De Lena C, Pasquini M. Memantine for refractory Obsessive-Compulsive disorder: protocol for a pragmatic, Double-blind, randomized, Parallel-Group, Placebo-Controlled, monocenter trial. JMIR Res Protoc. 2023;12:e39223.","journal-title":"JMIR Res Protoc"},{"issue":"2","key":"6856_CR13","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/j.pnpbp.2007.10.002","volume":"32","author":"S Selek","year":"2008","unstructured":"Selek S, Herken H, Bulut M, Ceylan MF, Celik H, Savas HA, et al. Oxidative imbalance in obsessive compulsive disorder patients: a total evaluation of oxidant-antioxidant status. Prog Neuropsychopharmacol Biol Psychiatry. 2008;32(2):487\u201391.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"11","key":"6856_CR14","doi-asserted-by":"publisher","first-page":"1831","DOI":"10.1016\/j.jpsychires.2013.08.010","volume":"47","author":"H Kandemir","year":"2013","unstructured":"Kandemir H, Abuhandan M, Aksoy N, Savik E, Kaya C. Oxidative imbalance in child and adolescent patients with obsessive compulsive disorder. J Psychiatr Res. 2013;47(11):1831\u20134.","journal-title":"J Psychiatr Res"},{"issue":"1","key":"6856_CR15","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.pnpbp.2008.10.004","volume":"33","author":"E Ozdemir","year":"2009","unstructured":"Ozdemir E, Cetinkaya S, Ersan S, Kucukosman S, Ersan EE. Serum selenium and plasma malondialdehyde levels and antioxidant enzyme activities in patients with obsessive-compulsive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33(1):62\u20135.","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"issue":"3","key":"6856_CR16","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/j.nbd.2012.02.012","volume":"46","author":"JD Long","year":"2012","unstructured":"Long JD, Matson WR, Juhl AR, Leavitt BR, Paulsen JS. 8OHdG as a marker for huntington disease progression. Neurobiol Dis. 2012;46(3):625\u201334.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"6856_CR17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cbi.2005.12.009","volume":"160","author":"M Valko","year":"2006","unstructured":"Valko M, Rhodes CJ, Moncol J, Izakovic M, Mazur M. Free radicals, metals and antioxidants in oxidative stress-induced cancer. Chem Biol Interact. 2006;160(1):1\u201340.","journal-title":"Chem Biol Interact"},{"issue":"2","key":"6856_CR18","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1111\/pcn.12362","volume":"70","author":"D Alici","year":"2016","unstructured":"Alici D, Bulbul F, Virit O, Unal A, Altindag A, Alpak G, et al. Evaluation of oxidative metabolism and oxidative DNA damage in patients with obsessive-compulsive disorder. Psychiatry Clin Neurosci. 2016;70(2):109\u201315.","journal-title":"Psychiatry Clin Neurosci"},{"issue":"9","key":"6856_CR19","doi-asserted-by":"publisher","first-page":"568","DOI":"10.5498\/wjp.v11.i9.568","volume":"11","author":"A Maraone","year":"2021","unstructured":"Maraone A, Tarsitani L, Pinucci I, Pasquini M. Antiglutamatergic agents for obsessive-compulsive disorder: where are we now and what are possible future prospects? World J Psychiatry. 2021;11(9):568\u201380.","journal-title":"World J Psychiatry"},{"key":"6856_CR20","doi-asserted-by":"publisher","first-page":"1362","DOI":"10.3389\/fphar.2019.01362","volume":"10","author":"AP Escobar","year":"2019","unstructured":"Escobar AP, Wendland JR, Ch\u00e1vez AE, Moya PR. The neuronal glutamate transporter EAAT3 in Obsessive-Compulsive disorder. Front Pharmacol. 2019;10:1362.","journal-title":"Front Pharmacol"},{"key":"6856_CR21","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.2147\/NDT.S211703","volume":"16","author":"S Karthik","year":"2020","unstructured":"Karthik S, Sharma LP, Narayanaswamy JC. Investigating the role of glutamate in Obsessive-Compulsive disorder: current perspectives. Neuropsychiatr Dis Treat. 2020;16:1003\u201313.","journal-title":"Neuropsychiatr Dis Treat"},{"issue":"1","key":"6856_CR22","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s00213-010-1808-9","volume":"210","author":"N Albelda","year":"2010","unstructured":"Albelda N, Bar-On N, Joel D. The role of NMDA receptors in the signal Attenuation rat model of obsessive-compulsive disorder. Psychopharmacology. 2010;210(1):13\u201324.","journal-title":"Psychopharmacology"},{"issue":"1","key":"6856_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40360-021-00534-6","volume":"22","author":"F Hadi","year":"2021","unstructured":"Hadi F, Kashefinejad S, Kamalzadeh L, Hoobehfekr S, Shalbafan M. Glutamatergic medications as adjunctive therapy for moderate to severe obsessive-compulsive disorder in adults: a systematic review and meta-analysis. BMC Pharmacol Toxicol. 2021;22(1):69.","journal-title":"BMC Pharmacol Toxicol"},{"issue":"9","key":"6856_CR24","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1007\/s40263-015-0272-9","volume":"29","author":"J Sarris","year":"2015","unstructured":"Sarris J, Oliver G, Camfield DA, Dean OM, Dowling N, Smith DJ, et al. N-Acetyl cysteine (NAC) in the treatment of Obsessive-Compulsive disorder: A 16-Week, Double-Blind, randomised, Placebo-Controlled study. CNS Drugs. 2015;29(9):801\u20139.","journal-title":"CNS Drugs"},{"issue":"7","key":"6856_CR25","doi-asserted-by":"publisher","first-page":"e766","DOI":"10.4088\/JCP.16m11101","volume":"78","author":"DLC Costa","year":"2017","unstructured":"Costa DLC, Diniz JB, Requena G, Joaquim MA, Pittenger C, Bloch MH, et al. Randomized, Double-Blind, Placebo-Controlled trial of N-Acetylcysteine augmentation for Treatment-Resistant Obsessive-Compulsive disorder. J Clin Psychiatry. 2017;78(7):e766\u201373.","journal-title":"J Clin Psychiatry"},{"key":"6856_CR26","doi-asserted-by":"crossref","unstructured":"Arabzadeh S, Shahhossenie M, Mesgarpour B, Rezaei F, Shalbafan MR, Ghiasi Z et al. L-carnosine as an adjuvant to fluvoxamine in treatment of obsessive compulsive disorder: A randomized double-blind study. Hum Psychopharmacol. 2017;32(4).","DOI":"10.1002\/hup.2584"},{"issue":"5","key":"6856_CR27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.4088\/JCP.09m05266gre","volume":"72","author":"HA Berlin","year":"2011","unstructured":"Berlin HA, Koran LM, Jenike MA, Shapira NA, Chaplin W, Pallanti S, et al. Double-blind, placebo-controlled trial of topiramate augmentation in treatment-resistant obsessive-compulsive disorder. J Clin Psychiatry. 2011;72(5):716\u201321.","journal-title":"J Clin Psychiatry"},{"issue":"10","key":"6856_CR28","first-page":"976","volume":"19","author":"H Afshar","year":"2014","unstructured":"Afshar H, Akuchekian S, Mahaky B, Zarean E. Topiramate augmentation in refractory obsessive-compulsive disorder: A randomized, double-blind, placebo-controlled trial. J Res Med Sci. 2014;19(10):976\u201381.","journal-title":"J Res Med Sci"},{"issue":"1","key":"6856_CR29","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1097\/JCP.0b013e3181c856de","volume":"30","author":"SE Stewart","year":"2010","unstructured":"Stewart SE, Jenike EA, Hezel DM, Stack DE, Dodman NH, Shuster L, et al. A single-blinded case-control study of memantine in severe obsessive-compulsive disorder. J Clin Psychopharmacol. 2010;30(1):34\u20139.","journal-title":"J Clin Psychopharmacol"},{"issue":"6","key":"6856_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1055\/s-0043-120268","volume":"51","author":"A Modarresi","year":"2018","unstructured":"Modarresi A, Sayyah M, Razooghi S, Eslami K, Javadi M, Kouti L. Memantine augmentation improves symptoms in serotonin reuptake Inhibitor-Refractory Obsessive-Compulsive disorder: A randomized controlled trial. Pharmacopsychiatry. 2018;51(6):263\u20139.","journal-title":"Pharmacopsychiatry"},{"key":"6856_CR31","doi-asserted-by":"publisher","first-page":"112602","DOI":"10.1016\/j.psychres.2019.112602","volume":"282","author":"A Modarresi","year":"2019","unstructured":"Modarresi A, Chaibakhsh S, Koulaeinejad N, Koupaei SR. A systematic review and meta-analysis: memantine augmentation in moderate to severe obsessive-compulsive disorder. Psychiatry Res. 2019;282:112602.","journal-title":"Psychiatry Res"},{"issue":"2","key":"6856_CR32","doi-asserted-by":"publisher","first-page":"100","DOI":"10.4103\/0976-500X.72352","volume":"1","author":"KF Schulz","year":"2010","unstructured":"Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. J Pharmacol Pharmacotherapeutics. 2010;1(2):100\u20137.","journal-title":"J Pharmacol Pharmacotherapeutics"},{"key":"6856_CR33","unstructured":"First MB. Diagnostic and statistical manual of mental disorders: DSM-5-TR. American Psychiatric Association Publishing; 2022."},{"issue":"2","key":"6856_CR34","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1037\/a0018492","volume":"22","author":"EA Storch","year":"2010","unstructured":"Storch EA, Rasmussen SA, Price LH, Larson MJ, Murphy TK, Goodman WK. Development and psychometric evaluation of the yale\u2013brown obsessive-compulsive scale\u2014second edition. Psychol Assess. 2010;22(2):223.","journal-title":"Psychol Assess"},{"issue":"3","key":"6856_CR35","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1586\/14737175.8.3.339","volume":"8","author":"J Zohar","year":"2008","unstructured":"Zohar J. Escitalopram in the treatment of obsessive\u2013compulsive disorder. Expert Rev Neurother. 2008;8(3):339\u201349.","journal-title":"Expert Rev Neurother"},{"issue":"11","key":"6856_CR36","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1001\/archpsyc.1989.01810110054008","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Delgado P, Heninger GR, et al. The yale-brown obsessive compulsive scale: II. Validity Archives Gen Psychiatry. 1989;46(11):1012\u20136.","journal-title":"Validity Archives Gen Psychiatry"},{"issue":"11","key":"6856_CR37","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.1001\/archpsyc.1989.01810110048007","volume":"46","author":"WK Goodman","year":"1989","unstructured":"Goodman WK, Price LH, Rasmussen SA, Mazure C, Fleischmann RL, Hill CL, et al. The Yale-Brown obsessive compulsive scale: I. Development, use, and reliability. Arch Gen Psychiatry. 1989;46(11):1006\u201311.","journal-title":"Arch Gen Psychiatry"},{"issue":"11","key":"6856_CR38","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1177\/0269881119878177","volume":"33","author":"M Shalbafan","year":"2019","unstructured":"Shalbafan M, Malekpour F, Tadayon Najafabadi B, Ghamari K, Dastgheib S-A, Mowla A, et al. Fluvoxamine combination therapy with Tropisetron for obsessive-compulsive disorder patients: A placebo-controlled, randomized clinical trial. J Psychopharmacol. 2019;33(11):1407\u201314.","journal-title":"J Psychopharmacol"},{"issue":"5","key":"6856_CR39","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1097\/YIC.0000000000000321","volume":"35","author":"F Yousefzadeh","year":"2020","unstructured":"Yousefzadeh F, Sahebolzamani E, Sadri A, Mortezaei A, Aqamolaei A, Mortazavi SH, et al. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. Int Clin Psychopharmacol. 2020;35(5):254\u201362.","journal-title":"Int Clin Psychopharmacol"},{"key":"6856_CR40","volume-title":"Deficits of executive functioning scale (BDEFS for adults)","author":"R Barkley","year":"2013","unstructured":"Barkley R. Deficits of executive functioning scale (BDEFS for adults). New York: Guilford Press; 2013."},{"key":"6856_CR41","volume-title":"Barkley deficits in executive functioning scale\u2013children and adolescents (","author":"RA Barkley","year":"2012","unstructured":"Barkley RA. Barkley deficits in executive functioning scale\u2013children and adolescents (. BDEFS-CA): Guilford Press; 2012."},{"issue":"1","key":"6856_CR42","first-page":"51","volume":"7","author":"A Mashhadi","year":"2015","unstructured":"Mashhadi A, Mirdoraghi F, Hosainzadeh-Maleki Z, Hasani J, Hamzeloo M. Factor structure, reliability and validity of Persian version of Barkley deficits in executive functioning scale (BDEFS)-Adult version. J Clin Psychol. 2015;7(1):51\u201362.","journal-title":"J Clin Psychol"},{"key":"6856_CR43","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.jpsychires.2018.07.008","volume":"104","author":"V Farnia","year":"2018","unstructured":"Farnia V, Gharehbaghi H, Alikhani M, Almasi A, Golshani S, Tatari F, et al. Efficacy and tolerability of adjunctive Gabapentin and memantine in obsessive compulsive disorder: Double-blind, randomized, placebo-controlled trial. J Psychiatr Res. 2018;104:137\u201343.","journal-title":"J Psychiatr Res"},{"issue":"2","key":"6856_CR44","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.jpsychires.2012.09.015","volume":"47","author":"A Ghaleiha","year":"2013","unstructured":"Ghaleiha A, Entezari N, Modabbernia A, Najand B, Askari N, Tabrizi M, et al. Memantine add-on in moderate to severe obsessive-compulsive disorder: randomized double-blind placebo-controlled study. J Psychiatr Res. 2013;47(2):175\u201380.","journal-title":"J Psychiatr Res"},{"issue":"4","key":"6856_CR45","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00213-013-3067-z","volume":"228","author":"M Haghighi","year":"2013","unstructured":"Haghighi M, Jahangard L, Mohammad-Beigi H, Bajoghli H, Hafezian H, Rahimi A, et al. In a double-blind, randomized and placebo-controlled trial, adjuvant memantine improved symptoms in inpatients suffering from refractory obsessive-compulsive disorders (OCD). Psychopharmacology. 2013;228(4):633\u201340.","journal-title":"Psychopharmacology"},{"issue":"1","key":"6856_CR46","doi-asserted-by":"publisher","first-page":"43","DOI":"10.3233\/JAD-180237","volume":"64","author":"T Kishi","year":"2018","unstructured":"Kishi T, Matsuda Y, Iwata N. Combination therapy of serotonin reuptake inhibitors and memantine for Obsessive- compulsive disorder: A Meta-Analysis of Double-Blind, randomized, Placebo-Controlled trials. J Alzheimers Dis. 2018;64(1):43\u20138.","journal-title":"J Alzheimers Dis"},{"issue":"12","key":"6856_CR47","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1176\/appi.ajp.2016.16080868","volume":"173","author":"CI Rodriguez","year":"2016","unstructured":"Rodriguez CI, Zwerling J, Kalanthroff E, Shen H, Filippou M, Jo B, et al. Effect of a novel NMDA receptor modulator, rapastinel (Formerly GLYX-13), in OCD: proof of concept. Am J Psychiatry. 2016;173(12):1239\u201341.","journal-title":"Am J Psychiatry"},{"key":"6856_CR48","doi-asserted-by":"publisher","first-page":"695","DOI":"10.2147\/JEP.S255375","volume":"12","author":"G Grassi","year":"2020","unstructured":"Grassi G, Cecchelli C, Vignozzi L, Pacini S. Investigational and experimental drugs to treat Obsessive-Compulsive disorder. J Exp Pharmacol. 2020;12:695\u2013706.","journal-title":"J Exp Pharmacol"},{"issue":"9","key":"6856_CR49","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1016\/S0006-3223(97)00443-5","volume":"43","author":"DR Rosenberg","year":"1998","unstructured":"Rosenberg DR, Keshavan MS. A.E. Bennett research award. Toward a neurodevelopmental model of of obsessive\u2013compulsive disorder. Biol Psychiatry. 1998;43(9):623\u201340.","journal-title":"Biol Psychiatry"},{"issue":"9","key":"6856_CR50","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1097\/00004583-200009000-00008","volume":"39","author":"DR Rosenberg","year":"2000","unstructured":"Rosenberg DR, MacMaster FP, Keshavan MS, Fitzgerald KD, Stewart CM, Moore GJ. Decrease in caudate glutamatergic concentrations in pediatric obsessive-compulsive disorder patients taking Paroxetine. J Am Acad Child Adolesc Psychiatry. 2000;39(9):1096\u2013103.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"9","key":"6856_CR51","doi-asserted-by":"publisher","first-page":"1146","DOI":"10.1097\/01.chi.0000132812.44664.2d","volume":"43","author":"DR Rosenberg","year":"2004","unstructured":"Rosenberg DR, Mirza Y, Russell A, Tang J, Smith JM, Banerjee SP, et al. Reduced anterior cingulate glutamatergic concentrations in childhood OCD and major depression versus healthy controls. J Am Acad Child Adolesc Psychiatry. 2004;43(9):1146\u201353.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"issue":"2","key":"6856_CR52","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1017\/S1461145701002401","volume":"4","author":"DR Rosenberg","year":"2001","unstructured":"Rosenberg DR, MacMillan SN, Moore GJ. Brain anatomy and chemistry May predict treatment response in paediatric obsessive\u2013compulsive disorder. Int J Neuropsychopharmacol. 2001;4(2):179\u201390.","journal-title":"Int J Neuropsychopharmacol"},{"key":"6856_CR53","doi-asserted-by":"publisher","first-page":"62","DOI":"10.2174\/1875397300802010062","volume":"2","author":"JT Ting","year":"2008","unstructured":"Ting JT, Feng G. Glutamatergic synaptic dysfunction and Obsessive-Compulsive disorder. Curr Chem Genomics. 2008;2:62\u201375.","journal-title":"Curr Chem Genomics"},{"issue":"2","key":"6856_CR54","doi-asserted-by":"publisher","first-page":"240","DOI":"10.9758\/cpn.2022.20.2.240","volume":"20","author":"F Kurhan","year":"2022","unstructured":"Kurhan F, Alp HH, I\u015f\u0131k M, Atan YS. The evaluation of thiol\/disulfide homeostasis and oxidative DNA damage in patients with obsessive compulsive disorder. Clin Psychopharmacol Neurosci. 2022;20(2):240\u20137.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"6856_CR55","doi-asserted-by":"crossref","unstructured":"Sheshachala K, Narayanaswamy JC. Glutamatergic augmentation strategies in obsessive\u2013compulsive disorder. Indian J Psychiatry. 2019;61(Suppl 1).","DOI":"10.4103\/psychiatry.IndianJPsychiatry_520_18"},{"issue":"40","key":"6856_CR56","doi-asserted-by":"publisher","first-page":"9686","DOI":"10.1523\/JNEUROSCI.1173-17.2017","volume":"37","author":"NG Glasgow","year":"2017","unstructured":"Glasgow NG, Povysheva NV, Azofeifa AM, Johnson JW. Memantine and ketamine differentially alter NMDA receptor desensitization. J Neurosci. 2017;37(40):9686.","journal-title":"J Neurosci"},{"issue":"4","key":"6856_CR57","first-page":"e37833","volume":"15","author":"AA Ferguson","year":"2023","unstructured":"Ferguson AA, Khan AI, Abuzainah B, Chaudhuri D, Khan KI, Al Shouli R, et al. Clinical effectiveness of N-Methyl-D-Aspartate (NMDA) receptor antagonists in adult Obsessive-Compulsive disorder (OCD) treatment: A systematic review. Cureus. 2023;15(4):e37833.","journal-title":"Cureus"},{"issue":"6","key":"6856_CR58","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1055\/s-0043-118665","volume":"51","author":"P Vl\u010dek","year":"2018","unstructured":"Vl\u010dek P, Pol\u00e1k J, Brunovsk\u00fd M, Hor\u00e1\u010dek J. Role of glutamatergic system in Obsessive-Compulsive disorder with possible therapeutic implications. Pharmacopsychiatry. 2018;51(6):229\u201342.","journal-title":"Pharmacopsychiatry"},{"issue":"3","key":"6856_CR59","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1016\/j.biopsych.2005.12.012","volume":"61","author":"SL Rauch","year":"2007","unstructured":"Rauch SL, Wedig MM, Wright CI, Martis B, McMullin KG, Shin LM, et al. Functional magnetic resonance imaging study of regional brain activation during implicit sequence learning in obsessive-compulsive disorder. Biol Psychiatry. 2007;61(3):330\u20136.","journal-title":"Biol Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06856-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12888-025-06856-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-025-06856-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T17:03:02Z","timestamp":1748883782000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-025-06856-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["6856"],"URL":"https:\/\/doi.org\/10.1186\/s12888-025-06856-7","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]},"assertion":[{"value":"7 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study received ethical approval from the Ethics Committee of Shiraz University of Medical Sciences (IR.SUMS.MED.REC.1402.093). All participants provided written informed consent prior to their inclusion in the study. The research was conducted in accordance with the ethical principles outlined in the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"561"}}